#Harvoni

A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.

Ninety-seven percent of the children were cured of hepatitis C.

The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

September 4, 2019, the U.S. FDA released their recent approval of new dosage forms of Sovaldi and Harvoni for children 3 to 12 years of age.

The presence of less studied HCV genotypes may compromise cure rates.

Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.

Researchers compared outcomes among those with and without hep C before and after Sovaldi was approved in late 2013.

Past research has found that proton pump inhibitors and histamine H2 agonists are associated with lower levels of certain hep C drugs.

Curing the virus was associated with a lower risk of liver cancer recurrence.

The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.

All women who completed follow-up in a small trial were cured, and none of their infants contracted the virus.

Indianapolis native Matt Heskett beat both opioid addiction and hep C. Now he’s paying his good fortune forward with activism and education.

What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.

This former paratrooper with the 82nd Airborne Division shares his experience with hepatitis C at Hep Stories.